Global Non-Alcoholic Steatohepatitis Biomarkers Market By Biomarker Type (Inflammation Biomarkers, Apoptosis Biomarkers, Fat Accumulation Biomarkers, Serum Biomarkers, Others (Fat metabolism, antioxidants, etc.)); By Diagnosis (Liver Biopsy, Histological assessment of liver tissue); By Patient Type (Adult, Pediatric); By End-User (Hospitals and Clinics, Research and Academic Institutes, Diagnostics, Pharma Companies, Others); By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2021 – 2029
Industry Trends
The human body encounters several health conditions, especially as individuals get older. One such health condition is referred to as non-alcoholic steatohepatitis, which is an inflammation in the liver caused by a heavy deposit of fat in the liver. The health condition comes under a more generalized term known as non-alcoholic fatty liver disease, also known as fatty liver in short. In many cases, the build-up of fat in the liver leads to the damage of liver cells, which in turn leads to the reduction in liver performance, especially in adults. A more complicated form of inflammation causes the liver to scar, and it leads to cirrhosis. The challenge associated with non-alcoholic steatohepatitis is that it is difficult to diagnose, as most individuals who have this condition feel normal. It may take several years until some of the symptoms associated with the condition start to show. The rising demand for faster diagnostics of non-alcoholic steatohepatitis using non-invasive measures is expected to lead to the growth of the global non-alcoholic steatohepatitis biomarkers market in the coming years.
COVID-19 Impact:
The COVID-19 pandemic has affected the lives of numerous individuals around the globe. The pandemic has caused a dynamic shift in the lifestyle of individuals, and conditions such as obesity and diabetes are on the rise. The pandemic is expected to have a positive impact on the global non-alcoholic steatohepatitis biomarkers market, as individuals who are affected by non-alcoholic steatohepatitis are at a higher risk of being adversely affected by the coronavirus. Studies show that those that have a history of being affected by non-alcoholic fatty liver disease or non-alcoholic steatohepatitis have a higher chance of being admitted to a hospital due to the complications arising with the infection of COVID-19 disease. Hence, government bodies around the globe are trying to identify individuals who have conditions such as non-alcoholic steatohepatitis, and provide added care in case of being affected by coronavirus. The awareness regarding non-alcoholic steatohepatitis has also seen a rise during the pandemic period, which in turn helps in the revenue growth of the global non-alcoholic steatohepatitis biomarkers market.
In terms of revenue, the global non-alcoholic steatohepatitis biomarkers market is growing at a CAGR of 23.45% over the forecast period (2021 – 2029). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Non-Alcoholic Steatohepatitis Biomarkers Market Revenue & Forecast, (US$ Million), 2021 – 2029
Patient Type Outlook:
Based on the types of patient in the global non-alcoholic steatohepatitis biomarkers market, adults have registered for a higher share in terms of revenue in 2020. The higher instances of non-alcoholic steatohepatitis amongst adults, coupled with the availability of less complex treatment plans for adults, is a major reason for the higher share of adults in the global non-alcoholic steatohepatitis biomarkers market. Research suggests that individuals are more likely to be affected by this health condition as they get older. The condition is more common in adults belonging to ethnicities like Hispanic, non-Hispanic white, and Asian American. Experts suggest that the difference in the likelihood of being affected by this health condition can be genetic in nature. There is a higher focus on diagnosing non-alcoholic steatohepatitis amongst adults, as it is generally more dangerous as compared to the same condition in children.
Region Outlook:
In terms of the regional revenue, North America accounted for the highest share of the revenue in the global non-alcoholic steatohepatitis biomarkers market in 2020. The higher awareness about non-alcoholic steatohepatitis amongst individuals in countries such as the U.S. and Canada, coupled with the availability of faster diagnostics and treatment methods in this region is a major reason for the higher share of North America in the global non-alcoholic steatohepatitis biomarkers market. In the U.S alone, as stated by the U.S. Department of Health and Human Services show that around 1.5% to 6.5% of U.S. adults have been affected by non-alcoholic steatohepatitis. Conditions such as obesity and type 2 diabetes are prevalent in the U.S., and individuals who have these conditions are at a higher risk of being affected by non-alcoholic steatohepatitis. Around 90% of the individuals who are extremely obese are expected to have non-alcoholic liver diseases. Also, the region is home to numerous market participants such as Pfizer, Merck and Bristol Myers, amongst others, and this in turn allows the individuals to get diagnosed at a faster rate. These factors enable North America to account for the larger share in the global non-alcoholic steatohepatitis biomarkers market.
Competitive Landscape
The report provides both, qualitative and quantitative research of the global non-alcoholic steatohepatitis biomarkers market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of key players operating in the global non-alcoholic steatohepatitis biomarkers market are Allergan, AstraZeneca, Bristol Myers Squibb Company, Echosens SA , Genfit SA, Gilead Sciences Inc, Madrigal Pharmaceuticals, Medpace, Merck & Co, Novartis AG, Novo Nordisk, Pfizer Inc, ProSciento+ NORDIC BIOSCIENCE, Siemens Healthcare GmbH, Viking Therapeutics, ZydusCadila, amongst others.
Global Non-Alcoholic Steatohepatitis Biomarkers Market
By Biomarker Type
- Inflammation Biomarkers
- Apoptosis Biomarkers
- Fat Accumulation Biomarkers
- Serum Biomarkers
- Others (Fat metabolism, antioxidants, etc.)
By Diagnosis
- Liver Biopsy
- Histological assessment of liver tissue
By Patient Type
- Adult
- Pediatric
By End-User
- Hospitals and Clinics
- Research& Academic Institutes
- Diagnostics
- Pharma Companies
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Forecast
Years: 2021 – 2029
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Non-Alcoholic Steatohepatitis
Biomarkers Market
6. Market Synopsis:
Non-Alcoholic Steatohepatitis Biomarkers
Market
7. Non-Alcoholic Steatohepatitis Biomarkers Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Non-Alcoholic Steatohepatitis Biomarkers
Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators: Non-Alcoholic Steatohepatitis
Biomarkers Market
7.6. Impact of COVID-19 on Non-Alcoholic Steatohepatitis
Biomarkers Market
8. Global Non-Alcoholic Steatohepatitis Biomarkers Market Analysis and Forecasts, 2021 – 2029
8.1. Overview
8.1.1. Global
Non-Alcoholic Steatohepatitis Biomarkers
Market Revenue (US$ Mn)
8.2. Global
Non-Alcoholic Steatohepatitis Biomarkers
Market Revenue (US$ Mn) and Forecasts, By Biomarker Type
8.2.1. Inflammation
Biomarkers
8.2.1.1. Definition
8.2.1.2. Market Forecast, 2021 – 2029
8.2.1.3. Compound Annual Growth Rate (CAGR)
8.2.1.4. Regional Bifurcation
8.2.1.4.1. North America
8.2.1.4.1.1. Market
Forecast, 2021 – 2029
8.2.1.4.2. Europe
8.2.1.4.2.1. Market
Forecast, 2021 – 2029
8.2.1.4.3. Asia Pacific
8.2.1.4.3.1. Market
Forecast, 2021 – 2029
8.2.1.4.4. Middle East and Africa
8.2.1.4.4.1. Market
Forecast, 2021 – 2029
8.2.1.4.5. Latin America
8.2.1.4.5.1. Market
Forecast, 2021 – 2029
8.2.2. Apoptosis
Biomarkers
8.2.2.1. Definition
8.2.2.2. Market Forecast, 2021 – 2029
8.2.2.3. Compound Annual Growth Rate (CAGR)
8.2.2.4. Regional Bifurcation
8.2.2.4.1. North America
8.2.2.4.1.1. Market
Forecast, 2021 – 2029
8.2.2.4.2. Europe
8.2.2.4.2.1. Market
Forecast, 2021 – 2029
8.2.2.4.3. Asia Pacific
8.2.2.4.3.1. Market
Forecast, 2021 – 2029
8.2.2.4.4. Middle East and Africa
8.2.2.4.4.1. Market
Forecast, 2021 – 2029
8.2.2.4.5. Latin America
8.2.2.4.5.1. Market
Forecast, 2021 – 2029
8.2.3. Fat
Accumulation Biomarkers
8.2.3.1. Definition
8.2.3.2. Market Forecast, 2021 – 2029
8.2.3.3. Compound Annual Growth Rate (CAGR)
8.2.3.4. Regional Bifurcation
8.2.3.4.1. North America
8.2.3.4.1.1. Market
Forecast, 2021 – 2029
8.2.3.4.2. Europe
8.2.3.4.2.1. Market
Forecast, 2021 – 2029
8.2.3.4.3. Asia Pacific
8.2.3.4.3.1. Market
Forecast, 2021 – 2029
8.2.3.4.4. Middle East and Africa
8.2.3.4.4.1. Market
Forecast, 2021 – 2029
8.2.3.4.5. Latin America
8.2.3.4.5.1. Market
Forecast, 2021 – 2029
8.2.4. Serum
Biomarkers
8.2.4.1. Definition
8.2.4.2. Market Forecast, 2021 – 2029
8.2.4.3. Compound Annual Growth Rate (CAGR)
8.2.4.4. Regional Bifurcation
8.2.4.4.1. North America
8.2.4.4.1.1. Market
Forecast, 2021 – 2029
8.2.4.4.2. Europe
8.2.4.4.2.1. Market
Forecast, 2021 – 2029
8.2.4.4.3. Asia Pacific
8.2.4.4.3.1. Market
Forecast, 2021 – 2029
8.2.4.4.4. Middle East and Africa
8.2.4.4.4.1. Market
Forecast, 2021 – 2029
8.2.4.4.5. Latin America
8.2.4.4.5.1. Market
Forecast, 2021 – 2029
8.2.5. Others
(Fat metabolism, antioxidants, etc.)
8.2.5.1. Definition
8.2.5.2. Market Forecast, 2021 – 2029
8.2.5.3. Compound Annual Growth Rate (CAGR)
8.2.5.4. Regional Bifurcation
8.2.5.4.1. North America
8.2.5.4.1.1. Market
Forecast, 2021 – 2029
8.2.5.4.2. Europe
8.2.5.4.2.1. Market
Forecast, 2021 – 2029
8.2.5.4.3. Asia Pacific
8.2.5.4.3.1. Market
Forecast, 2021 – 2029
8.2.5.4.4. Middle East and Africa
8.2.5.4.4.1. Market
Forecast, 2021 – 2029
8.2.5.4.5. Latin America
8.2.5.4.5.1. Market
Forecast, 2021 – 2029
8.3. Key
Segment for Channeling Investments
8.3.1. By
Biomarker Type
9. Global Non-Alcoholic Steatohepatitis Biomarkers Market Analysis and Forecasts, 2021 – 2029
9.1. Overview
9.2. Global
Non-Alcoholic Steatohepatitis Biomarkers
Market Revenue (US$ Mn) and Forecasts, By Diagnosis
9.2.1. Liver
Biopsy
9.2.1.1. Definition
9.2.1.2. Market Forecast, 2021 – 2029
9.2.1.3. Compound Annual Growth Rate (CAGR)
9.2.1.4. Regional Bifurcation
9.2.1.4.1. North America
9.2.1.4.1.1. Market
Forecast, 2021 – 2029
9.2.1.4.2. Europe
9.2.1.4.2.1. Market
Forecast, 2021 – 2029
9.2.1.4.3. Asia Pacific
9.2.1.4.3.1. Market
Forecast, 2021 – 2029
9.2.1.4.4. Middle East and Africa
9.2.1.4.4.1. Market
Forecast, 2021 – 2029
9.2.1.4.5. Latin America
9.2.1.4.5.1. Market
Forecast, 2021 – 2029
9.2.2. Histological
assessment of liver tissue
9.2.2.1. Definition
9.2.2.2. Market Forecast, 2021 – 2029
9.2.2.3. Compound Annual Growth Rate (CAGR)
9.2.2.4. Regional Bifurcation
9.2.2.4.1. North America
9.2.2.4.1.1. Market
Forecast, 2021 – 2029
9.2.2.4.2. Europe
9.2.2.4.2.1. Market
Forecast, 2021 – 2029
9.2.2.4.3. Asia Pacific
9.2.2.4.3.1. Market
Forecast, 2021 – 2029
9.2.2.4.4. Middle East and Africa
9.2.2.4.4.1. Market
Forecast, 2021 – 2029
9.2.2.4.5. Latin America
9.2.2.4.5.1. Market
Forecast, 2021 – 2029
9.3. Key
Segment for Channeling Investments
9.3.1. By
Diagnosis
10. Global Non-Alcoholic Steatohepatitis Biomarkers Market Analysis and Forecasts, 2021 – 2029
10.1. Overview
10.2. Global
Non-Alcoholic Steatohepatitis Biomarkers
Market Revenue (US$ Mn) and Forecasts, By Patient Type
10.2.1. Adult
10.2.1.1. Definition
10.2.1.2. Market Forecast, 2021 – 2029
10.2.1.3. Compound Annual Growth Rate (CAGR)
10.2.1.4. Regional Bifurcation
10.2.1.4.1. North America
10.2.1.4.1.1.
Market Forecast, 2021 – 2029
10.2.1.4.2. Europe
10.2.1.4.2.1.
Market Forecast, 2021 – 2029
10.2.1.4.3. Asia Pacific
10.2.1.4.3.1.
Market Forecast, 2021 – 2029
10.2.1.4.4. Middle East and Africa
10.2.1.4.4.1.
Market Forecast, 2021 – 2029
10.2.1.4.5. Latin America
10.2.1.4.5.1.
Market Forecast, 2021 – 2029
10.2.2. Pediatric
10.2.2.1. Definition
10.2.2.2. Market Forecast, 2021 – 2029
10.2.2.3. Compound Annual Growth Rate (CAGR)
10.2.2.4. Regional Bifurcation
10.2.2.4.1. North America
10.2.2.4.1.1.
Market Forecast, 2021 – 2029
10.2.2.4.2. Europe
10.2.2.4.2.1.
Market Forecast, 2021 – 2029
10.2.2.4.3. Asia Pacific
10.2.2.4.3.1.
Market Forecast, 2021 – 2029
10.2.2.4.4. Middle East and Africa
10.2.2.4.4.1.
Market Forecast, 2021 – 2029
10.2.2.4.5. Latin America
10.2.2.4.5.1.
Market Forecast, 2021 – 2029
10.2.2.4.5.2.
10.3. Key
Segment for Channeling Investments
10.3.1. By
Patient Type
11. Global Non-Alcoholic Steatohepatitis Biomarkers Market Analysis and Forecasts, 2021 – 2029
11.1. Overview
11.2. Global
Non-Alcoholic Steatohepatitis Biomarkers
Market Revenue (US$ Mn) and Forecasts, By End-User
11.2.1. Hospitals
and Clinics
11.2.1.1. Definition
11.2.1.2. Market Forecast, 2021 – 2029
11.2.1.3. Compound Annual Growth Rate (CAGR)
11.2.1.4. Regional Bifurcation
11.2.1.4.1. North America
11.2.1.4.1.1.
Market Forecast, 2021 – 2029
11.2.1.4.2. Europe
11.2.1.4.2.1.
Market Forecast, 2021 – 2029
11.2.1.4.3. Asia Pacific
11.2.1.4.3.1.
Market Forecast, 2021 – 2029
11.2.1.4.4. Middle East and Africa
11.2.1.4.4.1.
Market Forecast, 2021 – 2029
11.2.1.4.5. Latin America
11.2.1.4.5.1.
Market Forecast, 2021 – 2029
11.2.2. Research
& Academic Institutes
11.2.2.1. Definition
11.2.2.2. Market Forecast, 2021 – 2029
11.2.2.3. Compound Annual Growth Rate (CAGR)
11.2.2.4. Regional Bifurcation
11.2.2.4.1. North America
11.2.2.4.1.1.
Market Forecast, 2021 – 2029
11.2.2.4.2. Europe
11.2.2.4.2.1.
Market Forecast, 2021 – 2029
11.2.2.4.3. Asia Pacific
11.2.2.4.3.1.
Market Forecast, 2021 – 2029
11.2.2.4.4. Middle East and Africa
11.2.2.4.4.1.
Market Forecast, 2021 – 2029
11.2.2.4.5. Latin America
11.2.2.4.5.1.
Market Forecast, 2021 – 2029
11.2.3. Diagnostics
11.2.3.1. Definition
11.2.3.2. Market Forecast, 2021 – 2029
11.2.3.3. Compound Annual Growth Rate (CAGR)
11.2.3.4. Regional Bifurcation
11.2.3.4.1. North America
11.2.3.4.1.1.
Market Forecast, 2021 – 2029
11.2.3.4.2. Europe
11.2.3.4.2.1.
Market Forecast, 2021 – 2029
11.2.3.4.3. Asia Pacific
11.2.3.4.3.1.
Market Forecast, 2021 – 2029
11.2.3.4.4. Middle East and Africa
11.2.3.4.4.1.
Market Forecast, 2021 – 2029
11.2.3.4.5. Latin America
11.2.3.4.5.1.
Market Forecast, 2021 – 2029
11.2.4. Pharma
Companies
11.2.4.1. Definition
11.2.4.2. Market Forecast, 2021 – 2029
11.2.4.3. Compound Annual Growth Rate (CAGR)
11.2.4.4. Regional Bifurcation
11.2.4.4.1. North America
11.2.4.4.1.1.
Market Forecast, 2021 – 2029
11.2.4.4.2. Europe
11.2.4.4.2.1.
Market Forecast, 2021 – 2029
11.2.4.4.3. Asia Pacific
11.2.4.4.3.1.
Market Forecast, 2021 – 2029
11.2.4.4.4. Middle East and Africa
11.2.4.4.4.1.
Market Forecast, 2021 – 2029
11.2.4.4.5. Latin America
11.2.4.4.5.1.
Market Forecast, 2021 – 2029
11.2.5. Others
11.2.5.1. Definition
11.2.5.2. Market Forecast, 2021 – 2029
11.2.5.3. Compound Annual Growth Rate (CAGR)
11.2.5.4. Regional Bifurcation
11.2.5.4.1. North America
11.2.5.4.1.1.
Market Forecast, 2021 – 2029
11.2.5.4.2. Europe
11.2.5.4.2.1.
Market Forecast, 2021 – 2029
11.2.5.4.3. Asia Pacific
11.2.5.4.3.1.
Market Forecast, 2021 – 2029
11.2.5.4.4. Middle East and Africa
11.2.5.4.4.1.
Market Forecast, 2021 – 2029
11.2.5.4.5. Latin America
11.2.5.4.5.1.
Market Forecast, 2021 – 2029
11.3. Key
Segment for Channeling Investments
11.3.1. By
End-User
12. North America Non-Alcoholic Steatohepatitis Biomarkers Market Analysis and Forecasts, 2021 - 2029
12.1. Overview
12.1.1. North
America Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn)
12.2. North
America Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Biomarker Type
12.2.1. Inflammation
Biomarkers
12.2.2. Apoptosis
Biomarkers
12.2.3. Fat
Accumulation Biomarkers
12.2.4. Serum
Biomarkers
12.2.5. Others
(Fat metabolism, antioxidants, etc.)
12.3. North
America Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
12.3.1. Liver
Biopsy
12.3.2. Histological
assessment of liver tissue
12.4. North
America Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Patient Type
12.4.1. Adult
12.4.2. Pediatric
12.5. North
America Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
End-User
12.5.1. Hospitals
and Clinics
12.5.2. Research
& Academic Institutes
12.5.3. Diagnostics
12.5.4. Pharma
Companies
12.5.5. Others
12.6. North
America Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Country
12.6.1. U.S
12.6.1.1. U.S Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Biomarker Type
12.6.1.1.1. Inflammation Biomarkers
12.6.1.1.2. Apoptosis Biomarkers
12.6.1.1.3. Fat Accumulation Biomarkers
12.6.1.1.4. Serum Biomarkers
12.6.1.1.5. Others (Fat metabolism, antioxidants, etc.)
12.6.1.2. U.S Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
12.6.1.2.1. Liver Biopsy
12.6.1.2.2. Histological assessment of liver tissue
12.6.1.3. U.S Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Patient Type
12.6.1.3.1. Adult
12.6.1.3.2. Pediatric
12.6.1.4. U.S Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
End-User
12.6.1.4.1. Hospitals and Clinics
12.6.1.4.2. Research & Academic Institutes
12.6.1.4.3. Diagnostics
12.6.1.4.4. Pharma Companies
12.6.1.4.5. Others
12.6.2. Canada
12.6.2.1. Canada Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Biomarker Type
12.6.2.1.1. Inflammation Biomarkers
12.6.2.1.2. Apoptosis Biomarkers
12.6.2.1.3. Fat Accumulation Biomarkers
12.6.2.1.4. Serum Biomarkers
12.6.2.1.5. Others (Fat metabolism, antioxidants, etc.)
12.6.2.2. Canada Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
12.6.2.2.1. Liver Biopsy
12.6.2.2.2. Histological assessment of liver tissue
12.6.2.3. Canada Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Patient Type
12.6.2.3.1. Adult
12.6.2.3.2. Pediatric
12.6.2.4. Canada Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
End-User
12.6.2.4.1. Hospitals and Clinics
12.6.2.4.2. Research & Academic Institutes
12.6.2.4.3. Diagnostics
12.6.2.4.4. Pharma Companies
12.6.2.4.5. Others
12.6.3. Mexico
12.6.3.1. Mexico Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Biomarker Type
12.6.3.1.1. Inflammation Biomarkers
12.6.3.1.2. Apoptosis Biomarkers
12.6.3.1.3. Fat Accumulation Biomarkers
12.6.3.1.4. Serum Biomarkers
12.6.3.1.5. Others (Fat metabolism, antioxidants, etc.)
12.6.3.2. Mexico Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
12.6.3.2.1. Liver Biopsy
12.6.3.2.2. Histological assessment of liver tissue
12.6.3.3. Mexico Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Patient Type
12.6.3.3.1. Adult
12.6.3.3.2. Pediatric
12.6.3.4. Mexico Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
End-User
12.6.3.4.1. Hospitals and Clinics
12.6.3.4.2. Research & Academic Institutes
12.6.3.4.3. Diagnostics
12.6.3.4.4. Pharma Companies
12.6.3.4.5. Others
12.6.4. Rest of
North America
12.6.4.1. Rest of North America Non-Alcoholic Steatohepatitis
Biomarkers Market Revenue (US$ Mn) and Forecasts,
By Biomarker Type
12.6.4.1.1. Inflammation Biomarkers
12.6.4.1.2. Apoptosis Biomarkers
12.6.4.1.3. Fat Accumulation Biomarkers
12.6.4.1.4. Serum Biomarkers
12.6.4.1.5. Others (Fat metabolism, antioxidants, etc.)
12.6.4.2. Rest of North America Non-Alcoholic Steatohepatitis
Biomarkers Market Revenue (US$ Mn) and Forecasts,
By Diagnosis
12.6.4.2.1. Liver Biopsy
12.6.4.2.2. Histological assessment of liver tissue
12.6.4.3. Rest of North America Non-Alcoholic Steatohepatitis
Biomarkers Market Revenue (US$ Mn) and
Forecasts, By Patient Type
12.6.4.3.1. Adult
12.6.4.3.2. Pediatric
12.6.4.4. Rest of North America Non-Alcoholic Steatohepatitis
Biomarkers Market Revenue (US$ Mn) and
Forecasts, By End-User
12.6.4.4.1. Hospitals and Clinics
12.6.4.4.2. Research & Academic Institutes
12.6.4.4.3. Diagnostics
12.6.4.4.4. Pharma Companies
12.6.4.4.5. Others
12.7. Key
Segment for Channeling Investments
12.7.1. By
Country
12.7.2. By
Biomarker Type
12.7.3. By
Diagnosis
12.7.4. By
Patient Type
12.7.5. By
End-User
13. Europe Non-Alcoholic Steatohepatitis Biomarkers Market Analysis and Forecasts, 2021 - 2029
13.1. Overview
13.1.1. Europe
Non-Alcoholic Steatohepatitis Biomarkers
Market Revenue (US$ Mn)
13.2. Europe
Non-Alcoholic Steatohepatitis Biomarkers
Market Revenue (US$ Mn) and Forecasts, By Biomarker Type
13.2.1. Inflammation
Biomarkers
13.2.2. Apoptosis
Biomarkers
13.2.3. Fat
Accumulation Biomarkers
13.2.4. Serum
Biomarkers
13.2.5. Others
(Fat metabolism, antioxidants, etc.)
13.3. Europe
Non-Alcoholic Steatohepatitis Biomarkers
Market Revenue (US$ Mn) and Forecasts, By Diagnosis
13.3.1. Liver
Biopsy
13.3.2. Histological
assessment of liver tissue
13.4. Europe
Non-Alcoholic Steatohepatitis Biomarkers
Market Revenue (US$ Mn) and Forecasts, By Patient Type
13.4.1. Adult
13.4.2. Pediatric
13.5. Europe
Non-Alcoholic Steatohepatitis Biomarkers
Market Revenue (US$ Mn) and Forecasts, By End-User
13.5.1. Hospitals
and Clinics
13.5.2. Research
& Academic Institutes
13.5.3. Diagnostics
13.5.4. Pharma
Companies
13.5.5. Others
13.6. Europe
Non-Alcoholic Steatohepatitis Biomarkers
Market Revenue (US$ Mn) and Forecasts, By Country
13.6.1. France
13.6.1.1. France Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Biomarker Type
13.6.1.1.1. Inflammation Biomarkers
13.6.1.1.2. Apoptosis Biomarkers
13.6.1.1.3. Fat Accumulation Biomarkers
13.6.1.1.4. Serum Biomarkers
13.6.1.1.5. Others (Fat metabolism, antioxidants, etc.)
13.6.1.2. France Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
13.6.1.2.1. Liver Biopsy
13.6.1.2.2. Histological assessment of liver tissue
13.6.1.3. France Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Patient Type
13.6.1.3.1. Adult
13.6.1.3.2. Pediatric
13.6.1.4. France Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
End-User
13.6.1.4.1. Hospitals and Clinics
13.6.1.4.2. Research & Academic Institutes
13.6.1.4.3. Diagnostics
13.6.1.4.4. Pharma Companies
13.6.1.4.5. Others
13.6.2. The UK
13.6.2.1. The UK Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Biomarker Type
13.6.2.1.1. Inflammation Biomarkers
13.6.2.1.2. Apoptosis Biomarkers
13.6.2.1.3. Fat Accumulation Biomarkers
13.6.2.1.4. Serum Biomarkers
13.6.2.1.5. Others (Fat metabolism, antioxidants, etc.)
13.6.2.2. The UK Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
13.6.2.2.1. Liver Biopsy
13.6.2.2.2. Histological assessment of liver tissue
13.6.2.3. The UK Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Patient Type
13.6.2.3.1. Adult
13.6.2.3.2. Pediatric
13.6.2.4. The UK Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
End-User
13.6.2.4.1. Hospitals and Clinics
13.6.2.4.2. Research & Academic Institutes
13.6.2.4.3. Diagnostics
13.6.2.4.4. Pharma Companies
13.6.2.4.5. Others
13.6.3. Spain
13.6.3.1. Spain Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Biomarker Type
13.6.3.1.1. Inflammation Biomarkers
13.6.3.1.2. Apoptosis Biomarkers
13.6.3.1.3. Fat Accumulation Biomarkers
13.6.3.1.4. Serum Biomarkers
13.6.3.1.5. Others (Fat metabolism, antioxidants, etc.)
13.6.3.2. Spain Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
13.6.3.2.1. Liver Biopsy
13.6.3.2.2. Histological assessment of liver tissue
13.6.3.3. Spain Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Patient Type
13.6.3.3.1. Adult
13.6.3.3.2. Pediatric
13.6.3.4. Spain Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
End-User
13.6.3.4.1. Hospitals and Clinics
13.6.3.4.2. Research & Academic Institutes
13.6.3.4.3. Diagnostics
13.6.3.4.4. Pharma Companies
13.6.3.4.5. Others
13.6.4. Germany
13.6.4.1. Germany Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Biomarker Type
13.6.4.1.1. Inflammation Biomarkers
13.6.4.1.2. Apoptosis Biomarkers
13.6.4.1.3. Fat Accumulation Biomarkers
13.6.4.1.4. Serum Biomarkers
13.6.4.1.5. Others (Fat metabolism, antioxidants, etc.)
13.6.4.2. Germany Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
13.6.4.2.1. Liver Biopsy
13.6.4.2.2. Histological assessment of liver tissue
13.6.4.3. Germany Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Patient Type
13.6.4.3.1. Adult
13.6.4.3.2. Pediatric
13.6.4.4. Germany Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
End-User
13.6.4.4.1. Hospitals and Clinics
13.6.4.4.2. Research & Academic Institutes
13.6.4.4.3. Diagnostics
13.6.4.4.4. Pharma Companies
13.6.4.4.5. Others
13.6.5. Italy
13.6.5.1. Italy Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Biomarker Type
13.6.5.1.1. Inflammation Biomarkers
13.6.5.1.2. Apoptosis Biomarkers
13.6.5.1.3. Fat Accumulation Biomarkers
13.6.5.1.4. Serum Biomarkers
13.6.5.1.5. Others (Fat metabolism, antioxidants, etc.)
13.6.5.2. Italy Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
13.6.5.2.1. Liver Biopsy
13.6.5.2.2. Histological assessment of liver tissue
13.6.5.3. Italy Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Patient Type
13.6.5.3.1. Adult
13.6.5.3.2. Pediatric
13.6.5.4. Italy Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
End-User
13.6.5.4.1. Hospitals and Clinics
13.6.5.4.2. Research & Academic Institutes
13.6.5.4.3. Diagnostics
13.6.5.4.4. Pharma Companies
13.6.5.4.5. Others
13.6.6. Nordic
Countries
13.6.6.1. Nordic Countries Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Biomarker Type
13.6.6.1.1. Inflammation Biomarkers
13.6.6.1.2. Apoptosis Biomarkers
13.6.6.1.3. Fat Accumulation Biomarkers
13.6.6.1.4. Serum Biomarkers
13.6.6.1.5. Others (Fat metabolism, antioxidants, etc.)
13.6.6.2. Nordic Countries Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
13.6.6.2.1. Liver Biopsy
13.6.6.2.2. Histological assessment of liver tissue
13.6.6.3. Nordic Countries Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Patient Type
13.6.6.3.1. Adult
13.6.6.3.2. Pediatric
13.6.6.4. Nordic Countries Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
End-User
13.6.6.4.1. Hospitals and Clinics
13.6.6.4.2. Research & Academic Institutes
13.6.6.4.3. Diagnostics
13.6.6.4.4. Pharma Companies
13.6.6.4.5. Others
13.6.6.5. Nordic Countries Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Country
13.6.6.5.1. Denmark
13.6.6.5.2. Finland
13.6.6.5.3. Iceland
13.6.6.5.4. Sweden
13.6.6.5.5. Norway
13.6.7. Benelux
Union
13.6.7.1. Benelux Union Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Biomarker Type
13.6.7.1.1. Inflammation Biomarkers
13.6.7.1.2. Apoptosis Biomarkers
13.6.7.1.3. Fat Accumulation Biomarkers
13.6.7.1.4. Serum Biomarkers
13.6.7.1.5. Others (Fat metabolism, antioxidants, etc.)
13.6.7.2. Benelux Union Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
13.6.7.2.1. Liver Biopsy
13.6.7.2.2. Histological assessment of liver tissue
13.6.7.3. Benelux Union Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Patient Type
13.6.7.3.1. Adult
13.6.7.3.2. Pediatric
13.6.7.4. Benelux Union Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
End-User
13.6.7.4.1. Hospitals and Clinics
13.6.7.4.2. Research & Academic Institutes
13.6.7.4.3. Diagnostics
13.6.7.4.4. Pharma Companies
13.6.7.4.5. Others
13.6.7.5. Benelux Union Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Country
13.6.7.5.1. Belgium
13.6.7.5.2. The Netherlands
13.6.7.5.3. Luxembourg
13.6.8. Rest of
Europe
13.6.8.1. Rest of Europe Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Biomarker Type
13.6.8.1.1. Inflammation Biomarkers
13.6.8.1.2. Apoptosis Biomarkers
13.6.8.1.3. Fat Accumulation Biomarkers
13.6.8.1.4. Serum Biomarkers
13.6.8.1.5. Others (Fat metabolism, antioxidants, etc.)
13.6.8.2. Rest of Europe Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
13.6.8.2.1. Liver Biopsy
13.6.8.2.2. Histological assessment of liver tissue
13.6.8.3. Rest of Europe Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Patient Type
13.6.8.3.1. Adult
13.6.8.3.2. Pediatric
13.6.8.4. Rest of Europe Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By End-User
13.6.8.4.1. Hospitals and Clinics
13.6.8.4.2. Research & Academic Institutes
13.6.8.4.3. Diagnostics
13.6.8.4.4. Pharma Companies
13.6.8.4.5. Others
13.7. Key
Segment for Channeling Investments
13.7.1. By
Country
13.7.2. By
Biomarker Type
13.7.3. By
Diagnosis
13.7.4. By
Patient Type
13.7.5. By
End-User
14. Asia Pacific Non-Alcoholic Steatohepatitis Biomarkers Market Analysis and Forecasts, 2021 - 2029
14.1. Overview
14.1.1. Asia
Pacific Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn)
14.2. Asia
Pacific Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Biomarker Type
14.2.1. Inflammation
Biomarkers
14.2.2. Apoptosis
Biomarkers
14.2.3. Fat
Accumulation Biomarkers
14.2.4. Serum
Biomarkers
14.2.5. Others
(Fat metabolism, antioxidants, etc.)
14.3. Asia
Pacific Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
14.3.1. Liver
Biopsy
14.3.2. Histological
assessment of liver tissue
14.4. Asia
Pacific Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Patient Type
14.4.1. Adult
14.4.2. Pediatric
14.5. Asia
Pacific Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
End-User
14.5.1. Hospitals
and Clinics
14.5.2. Research
& Academic Institutes
14.5.3. Diagnostics
14.5.4. Pharma
Companies
14.5.5. Others
14.6. Asia
Pacific Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Country
14.6.1. China
14.6.1.1. China Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Biomarker Type
14.6.1.1.1. Inflammation Biomarkers
14.6.1.1.2. Apoptosis Biomarkers
14.6.1.1.3. Fat Accumulation Biomarkers
14.6.1.1.4. Serum Biomarkers
14.6.1.1.5. Others (Fat metabolism, antioxidants, etc.)
14.6.1.2. China Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
14.6.1.2.1. Liver Biopsy
14.6.1.2.2. Histological assessment of liver tissue
14.6.1.3. China Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Patient Type
14.6.1.3.1. Adult
14.6.1.3.2. Pediatric
14.6.1.4. China Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
End-User
14.6.1.4.1. Hospitals and Clinics
14.6.1.4.2. Research & Academic Institutes
14.6.1.4.3. Diagnostics
14.6.1.4.4. Pharma Companies
14.6.1.4.5. Others
14.6.2. Japan
14.6.2.1. Japan Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Biomarker Type
14.6.2.1.1. Inflammation Biomarkers
14.6.2.1.2. Apoptosis Biomarkers
14.6.2.1.3. Fat Accumulation Biomarkers
14.6.2.1.4. Serum Biomarkers
14.6.2.1.5. Others (Fat metabolism, antioxidants, etc.)
14.6.2.2. Japan Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
14.6.2.2.1. Liver Biopsy
14.6.2.2.2. Histological assessment of liver tissue
14.6.2.3. Japan Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Patient Type
14.6.2.3.1. Adult
14.6.2.3.2. Pediatric
14.6.2.4. Japan Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
End-User
14.6.2.4.1. Hospitals and Clinics
14.6.2.4.2. Research & Academic Institutes
14.6.2.4.3. Diagnostics
14.6.2.4.4. Pharma Companies
14.6.2.4.5. Others
14.6.3. India
14.6.3.1. India Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Biomarker Type
14.6.3.1.1. Inflammation Biomarkers
14.6.3.1.2. Apoptosis Biomarkers
14.6.3.1.3. Fat Accumulation Biomarkers
14.6.3.1.4. Serum Biomarkers
14.6.3.1.5. Others (Fat metabolism, antioxidants, etc.)
14.6.3.2. India Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
14.6.3.2.1. Liver Biopsy
14.6.3.2.2. Histological assessment of liver tissue
14.6.3.3. India Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Patient Type
14.6.3.3.1. Adult
14.6.3.3.2. Pediatric
14.6.3.4. India Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
End-User
14.6.3.4.1. Hospitals and Clinics
14.6.3.4.2. Research & Academic Institutes
14.6.3.4.3. Diagnostics
14.6.3.4.4. Pharma Companies
14.6.3.4.5. Others
14.6.4. New
Zealand
14.6.4.1. New Zealand Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Biomarker Type
14.6.4.1.1. Inflammation Biomarkers
14.6.4.1.2. Apoptosis Biomarkers
14.6.4.1.3. Fat Accumulation Biomarkers
14.6.4.1.4. Serum Biomarkers
14.6.4.1.5. Others (Fat metabolism, antioxidants, etc.)
14.6.4.2. New Zealand Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
14.6.4.2.1. Liver Biopsy
14.6.4.2.2. Histological assessment of liver tissue
14.6.4.3. New Zealand Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Patient Type
14.6.4.3.1. Adult
14.6.4.3.2. Pediatric
14.6.4.4. New Zealand Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
End-User
14.6.4.4.1. Hospitals and Clinics
14.6.4.4.2. Research & Academic Institutes
14.6.4.4.3. Diagnostics
14.6.4.4.4. Pharma Companies
14.6.4.4.5. Others
14.6.5. Australia
14.6.5.1. Australia Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Biomarker Type
14.6.5.1.1. Inflammation Biomarkers
14.6.5.1.2. Apoptosis Biomarkers
14.6.5.1.3. Fat Accumulation Biomarkers
14.6.5.1.4. Serum Biomarkers
14.6.5.1.5. Others (Fat metabolism, antioxidants, etc.)
14.6.5.2. Australia Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
14.6.5.2.1. Liver Biopsy
14.6.5.2.2. Histological assessment of liver tissue
14.6.5.3. Australia Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Patient Type
14.6.5.3.1. Adult
14.6.5.3.2. Pediatric
14.6.5.4. Australia Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
End-User
14.6.5.4.1. Hospitals and Clinics
14.6.5.4.2. Research & Academic Institutes
14.6.5.4.3. Diagnostics
14.6.5.4.4. Pharma Companies
14.6.5.4.5. Others
14.6.6. South
Korea
14.6.6.1. South Korea Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Biomarker Type
14.6.6.1.1. Inflammation Biomarkers
14.6.6.1.2. Apoptosis Biomarkers
14.6.6.1.3. Fat Accumulation Biomarkers
14.6.6.1.4. Serum Biomarkers
14.6.6.1.5. Others (Fat metabolism, antioxidants, etc.)
14.6.6.2. South Korea Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
14.6.6.2.1. Liver Biopsy
14.6.6.2.2. Histological assessment of liver tissue
14.6.6.3. South Korea Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Patient Type
14.6.6.3.1. Adult
14.6.6.3.2. Pediatric
14.6.6.4. South Korea Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
End-User
14.6.6.4.1. Hospitals and Clinics
14.6.6.4.2. Research & Academic Institutes
14.6.6.4.3. Diagnostics
14.6.6.4.4. Pharma Companies
14.6.6.4.5. Others
14.6.7. Southeast
Asia
14.6.7.1. Southeast Asia Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Biomarker Type
14.6.7.1.1. Inflammation Biomarkers
14.6.7.1.2. Apoptosis Biomarkers
14.6.7.1.3. Fat Accumulation Biomarkers
14.6.7.1.4. Serum Biomarkers
14.6.7.1.5. Others (Fat metabolism, antioxidants, etc.)
14.6.7.2. Southeast Asia Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
14.6.7.2.1. Liver Biopsy
14.6.7.2.2. Histological assessment of liver tissue
14.6.7.3. Southeast Asia Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Patient Type
14.6.7.3.1. Adult
14.6.7.3.2. Pediatric
14.6.7.4. Southeast Asia Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
End-User
14.6.7.4.1. Hospitals and Clinics
14.6.7.4.2. Research & Academic Institutes
14.6.7.4.3. Diagnostics
14.6.7.4.4. Pharma Companies
14.6.7.4.5. Others
14.6.7.5. Southeast Asia Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Country
14.6.7.5.1. Indonesia
14.6.7.5.2. Thailand
14.6.7.5.3. Malaysia
14.6.7.5.4. Singapore
14.6.7.5.5. Rest of Southeast Asia
14.6.8. Rest of
Asia Pacific
14.6.8.1. Rest of Asia Pacific Non-Alcoholic Steatohepatitis
Biomarkers Market Revenue (US$ Mn) and
Forecasts, By Biomarker Type
14.6.8.1.1. Inflammation Biomarkers
14.6.8.1.2. Apoptosis Biomarkers
14.6.8.1.3. Fat Accumulation Biomarkers
14.6.8.1.4. Serum Biomarkers
14.6.8.1.5. Others (Fat metabolism, antioxidants, etc.)
14.6.8.2. Rest of Asia Pacific Non-Alcoholic Steatohepatitis
Biomarkers Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
14.6.8.2.1. Liver Biopsy
14.6.8.2.2. Histological assessment of liver tissue
14.6.8.3. Rest of Asia Pacific Non-Alcoholic Steatohepatitis
Biomarkers Market Revenue (US$ Mn) and
Forecasts, By Patient Type
14.6.8.3.1. Adult
14.6.8.3.2. Pediatric
14.6.8.4. Rest of Asia Pacific Non-Alcoholic Steatohepatitis
Biomarkers Market Revenue (US$ Mn) and
Forecasts, By End-User
14.6.8.4.1. Hospitals and Clinics
14.6.8.4.2. Research & Academic Institutes
14.6.8.4.3. Diagnostics
14.6.8.4.4. Pharma Companies
14.6.8.4.5. Others
14.7. Key
Segment for Channeling Investments
14.7.1. By
Country
14.7.2. By
Biomarker Type
14.7.3. By Diagnosis
14.7.4. By
Patient Type
14.7.5. By
End-User
15. Middle East and Africa Non-Alcoholic Steatohepatitis
Biomarkers Market Analysis and
Forecasts, 2021 - 2029
15.1. Overview
15.1.1. Middle
East and Africa Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn)
15.2. Middle
East and Africa Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Biomarker Type
15.2.1. Inflammation
Biomarkers
15.2.2. Apoptosis
Biomarkers
15.2.3. Fat
Accumulation Biomarkers
15.2.4. Serum
Biomarkers
15.2.5. Others
(Fat metabolism, antioxidants, etc.)
15.3. Middle
East and Africa Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
15.3.1. Liver
Biopsy
15.3.2. Histological
assessment of liver tissue
15.4. Middle
East and Africa Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Patient Type
15.4.1. Adult
15.4.2. Pediatric
15.5. Middle
East and Africa Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
End-User
15.5.1. Hospitals
and Clinics
15.5.2. Research
& Academic Institutes
15.5.3. Diagnostics
15.5.4. Pharma
Companies
15.5.5. Others
15.6. Middle
East and Africa Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Country
15.6.1. Saudi
Arabia
15.6.1.1. Saudi Arabia Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Biomarker Type
15.6.1.1.1. Inflammation Biomarkers
15.6.1.1.2. Apoptosis Biomarkers
15.6.1.1.3. Fat Accumulation Biomarkers
15.6.1.1.4. Serum Biomarkers
15.6.1.1.5. Others (Fat metabolism, antioxidants, etc.)
15.6.1.2. Saudi Arabia Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
15.6.1.2.1. Liver Biopsy
15.6.1.2.2. Histological assessment of liver tissue
15.6.1.3. Saudi Arabia Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Patient Type
15.6.1.3.1. Adult
15.6.1.3.2. Pediatric
15.6.1.4. Saudi Arabia Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
End-User
15.6.1.4.1. Hospitals and Clinics
15.6.1.4.2. Research & Academic Institutes
15.6.1.4.3. Diagnostics
15.6.1.4.4. Pharma Companies
15.6.1.4.5. Others
15.6.2. UAE
15.6.2.1. UAE Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Biomarker Type
15.6.2.1.1. Inflammation Biomarkers
15.6.2.1.2. Apoptosis Biomarkers
15.6.2.1.3. Fat Accumulation Biomarkers
15.6.2.1.4. Serum Biomarkers
15.6.2.1.5. Others (Fat metabolism, antioxidants, etc.)
15.6.2.2. UAE Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
15.6.2.2.1. Liver Biopsy
15.6.2.2.2. Histological assessment of liver tissue
15.6.2.3. UAE Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Patient Type
15.6.2.3.1. Adult
15.6.2.3.2. Pediatric
15.6.2.4. UAE Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
End-User
15.6.2.4.1. Hospitals and Clinics
15.6.2.4.2. Research & Academic Institutes
15.6.2.4.3. Diagnostics
15.6.2.4.4. Pharma Companies
15.6.2.4.5. Others
15.6.3. Egypt
15.6.3.1. Egypt Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Biomarker Type
15.6.3.1.1. Inflammation Biomarkers
15.6.3.1.2. Apoptosis Biomarkers
15.6.3.1.3. Fat Accumulation Biomarkers
15.6.3.1.4. Serum Biomarkers
15.6.3.1.5. Others (Fat metabolism, antioxidants, etc.)
15.6.3.2. Egypt Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
15.6.3.2.1. Liver Biopsy
15.6.3.2.2. Histological assessment of liver tissue
15.6.3.3. Egypt Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Patient Type
15.6.3.3.1. Adult
15.6.3.3.2. Pediatric
15.6.3.4. Egypt Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
End-User
15.6.3.4.1. Hospitals and Clinics
15.6.3.4.2. Research & Academic Institutes
15.6.3.4.3. Diagnostics
15.6.3.4.4. Pharma Companies
15.6.3.4.5. Others
15.6.4. Kuwait
15.6.4.1. Kuwait Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Biomarker Type
15.6.4.1.1. Inflammation Biomarkers
15.6.4.1.2. Apoptosis Biomarkers
15.6.4.1.3. Fat Accumulation Biomarkers
15.6.4.1.4. Serum Biomarkers
15.6.4.1.5. Others (Fat metabolism, antioxidants, etc.)
15.6.4.2. Kuwait Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
15.6.4.2.1. Liver Biopsy
15.6.4.2.2. Histological assessment of liver tissue
15.6.4.3. Kuwait Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Patient Type
15.6.4.3.1. Adult
15.6.4.3.2. Pediatric
15.6.4.4. Kuwait Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
End-User
15.6.4.4.1. Hospitals and Clinics
15.6.4.4.2. Research & Academic Institutes
15.6.4.4.3. Diagnostics
15.6.4.4.4. Pharma Companies
15.6.4.4.5. Others
15.6.5. South
Africa
15.6.5.1. South Africa Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Biomarker Type
15.6.5.1.1. Inflammation Biomarkers
15.6.5.1.2. Apoptosis Biomarkers
15.6.5.1.3. Fat Accumulation Biomarkers
15.6.5.1.4. Serum Biomarkers
15.6.5.1.5. Others (Fat metabolism, antioxidants, etc.)
15.6.5.2. South Africa Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
15.6.5.2.1. Liver Biopsy
15.6.5.2.2. Histological assessment of liver tissue
15.6.5.3. South Africa Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Patient Type
15.6.5.3.1. Adult
15.6.5.3.2. Pediatric
15.6.5.4. South Africa Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
End-User
15.6.5.4.1. Hospitals and Clinics
15.6.5.4.2. Research & Academic Institutes
15.6.5.4.3. Diagnostics
15.6.5.4.4. Pharma Companies
15.6.5.4.5. Others
15.6.6. Rest of
Middle East & Africa
15.6.6.1. Rest of Middle East & Africa Non-Alcoholic Steatohepatitis
Biomarkers Market Revenue (US$ Mn) and
Forecasts, By Biomarker Type
15.6.6.1.1. Inflammation Biomarkers
15.6.6.1.2. Apoptosis Biomarkers
15.6.6.1.3. Fat Accumulation Biomarkers
15.6.6.1.4. Serum Biomarkers
15.6.6.1.5. Others (Fat metabolism, antioxidants, etc.)
15.6.6.2. Rest of Middle East & Africa Non-Alcoholic Steatohepatitis
Biomarkers Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
15.6.6.2.1. Liver Biopsy
15.6.6.2.2. Histological assessment of liver tissue
15.6.6.3. Rest of Middle East & Africa Non-Alcoholic Steatohepatitis
Biomarkers Market Revenue (US$ Mn) and
Forecasts, By Patient Type
15.6.6.3.1. Adult
15.6.6.3.2. Pediatric
15.6.6.4. Rest of Middle East & Africa Non-Alcoholic Steatohepatitis
Biomarkers Market Revenue (US$ Mn) and
Forecasts, By End-User
15.6.6.4.1. Hospitals and Clinics
15.6.6.4.2. Research & Academic Institutes
15.6.6.4.3. Diagnostics
15.6.6.4.4. Pharma Companies
15.6.6.4.5. Others
15.7. Key
Segment for Channeling Investments
15.7.1. By
Country
15.7.2. By
Biomarker Type
15.7.3. By
Diagnosis
15.7.4. By
Patient Type
15.7.5. By
End-User
16. Latin America Non-Alcoholic Steatohepatitis Biomarkers Market Analysis and Forecasts, 2021 - 2029
16.1. Overview
16.1.1. Latin
America Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn)
16.2. Latin
America Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Biomarker Type
16.2.1. Inflammation
Biomarkers
16.2.2. Apoptosis
Biomarkers
16.2.3. Fat
Accumulation Biomarkers
16.2.4. Serum
Biomarkers
16.2.5. Others
(Fat metabolism, antioxidants, etc.)
16.3. Latin
America Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
16.3.1. Liver
Biopsy
16.3.2. Histological
assessment of liver tissue
16.4. Latin
America Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Patient Type
16.4.1. Adult
16.4.2. Pediatric
16.5. Latin
America Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
End-User
16.5.1. Hospitals
and Clinics
16.5.2. Research
& Academic Institutes
16.5.3. Diagnostics
16.5.4. Pharma
Companies
16.5.5. Others
16.6. Latin
America Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Country
16.6.1. Brazil
16.6.1.1. Brazil Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Biomarker Type
16.6.1.1.1. Inflammation Biomarkers
16.6.1.1.2. Apoptosis Biomarkers
16.6.1.1.3. Fat Accumulation Biomarkers
16.6.1.1.4. Serum Biomarkers
16.6.1.1.5. Others (Fat metabolism, antioxidants, etc.)
16.6.1.2. Brazil Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
16.6.1.2.1. Liver Biopsy
16.6.1.2.2. Histological assessment of liver tissue
16.6.1.3. Brazil Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Patient Type
16.6.1.3.1. Adult
16.6.1.3.2. Pediatric
16.6.1.4. Brazil Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
End-User
16.6.1.4.1. Hospitals and Clinics
16.6.1.4.2. Research & Academic Institutes
16.6.1.4.3. Diagnostics
16.6.1.4.4. Pharma Companies
16.6.1.4.5. Others
16.6.2. Argentina
16.6.2.1. Argentina Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Biomarker Type
16.6.2.1.1. Inflammation Biomarkers
16.6.2.1.2. Apoptosis Biomarkers
16.6.2.1.3. Fat Accumulation Biomarkers
16.6.2.1.4. Serum Biomarkers
16.6.2.1.5. Others (Fat metabolism, antioxidants, etc.)
16.6.2.2. Argentina Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
16.6.2.2.1. Liver Biopsy
16.6.2.2.2. Histological assessment of liver tissue
16.6.2.3. Argentina Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
Patient Type
16.6.2.3.1. Adult
16.6.2.3.2. Pediatric
16.6.2.4. Argentina Non-Alcoholic Steatohepatitis Biomarkers Market Revenue (US$ Mn) and Forecasts, By
End-User
16.6.2.4.1. Hospitals and Clinics
16.6.2.4.2. Research & Academic Institutes
16.6.2.4.3. Diagnostics
16.6.2.4.4. Pharma Companies
16.6.2.4.5. Others
16.6.3. Rest of
Latin America
16.6.3.1. Rest of Latin America Non-Alcoholic Steatohepatitis
Biomarkers Market Revenue (US$ Mn) and
Forecasts, By Biomarker Type
16.6.3.1.1. Inflammation Biomarkers
16.6.3.1.2. Apoptosis Biomarkers
16.6.3.1.3. Fat Accumulation Biomarkers
16.6.3.1.4. Serum Biomarkers
16.6.3.1.5. Others (Fat metabolism, antioxidants, etc.)
16.6.3.2. Rest of Latin America Non-Alcoholic Steatohepatitis
Biomarkers Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
16.6.3.2.1. Liver Biopsy
16.6.3.2.2. Histological assessment of liver tissue
16.6.3.3. Rest of Latin America Non-Alcoholic Steatohepatitis
Biomarkers Market Revenue (US$ Mn) and
Forecasts, By Patient Type
16.6.3.3.1. Adult
16.6.3.3.2. Pediatric
16.6.3.4. Rest of Latin America Non-Alcoholic Steatohepatitis
Biomarkers Market Revenue (US$ Mn) and
Forecasts, By End-User
16.6.3.4.1. Hospitals and Clinics
16.6.3.4.2. Research & Academic Institutes
16.6.3.4.3. Diagnostics
16.6.3.4.4. Pharma Companies
16.6.3.4.5. Others
16.7. Key
Segment for Channeling Investments
16.7.1. By
Country
16.7.2. By
Biomarker Type
16.7.3. By
Diagnosis
16.7.4. By
Patient Type
16.7.5. By
End-User
17. Competitive Benchmarking
17.1. Global
Presence and Growth Strategies
17.1.1. Mergers
and Acquisitions
17.1.2. Product
Launches
17.1.3. Investments
Trends
17.1.4. R&D
Initiatives
18. Player Profiles
18.1. Allergan
18.1.1. Company
Details
18.1.2. Company
Overview
18.1.3. Product
Offerings
18.1.4. Key
Developments
18.1.5. Financial
Analysis
18.1.6. SWOT
Analysis
18.1.7. Business
Strategies
18.2. AstraZeneca
18.2.1. Company
Details
18.2.2. Company
Overview
18.2.3. Product
Offerings
18.2.4. Key
Developments
18.2.5. Financial
Analysis
18.2.6. SWOT
Analysis
18.2.7. Business
Strategies
18.3. Bristol
Myers Squibb Company
18.3.1. Company
Details
18.3.2. Company
Overview
18.3.3. Product
Offerings
18.3.4. Key
Developments
18.3.5. Financial
Analysis
18.3.6. SWOT
Analysis
18.3.7. Business
Strategies
18.4. Echosens
SA
18.4.1. Company
Details
18.4.2. Company
Overview
18.4.3. Product
Offerings
18.4.4. Key
Developments
18.4.5. Financial
Analysis
18.4.6. SWOT
Analysis
18.4.7. Business
Strategies
18.5. Genfit SA
18.5.1. Company
Details
18.5.2. Company
Overview
18.5.3. Product
Offerings
18.5.4. Key
Developments
18.5.5. Financial
Analysis
18.5.6. SWOT Analysis
18.5.7. Business
Strategies
18.6. Gilead
Sciences Inc
18.6.1. Company
Details
18.6.2. Company
Overview
18.6.3. Product
Offerings
18.6.4. Key
Developments
18.6.5. Financial
Analysis
18.6.6. SWOT
Analysis
18.6.7. Business
Strategies
18.7. Madrigal
Pharmaceuticals
18.7.1. Company
Details
18.7.2. Company
Overview
18.7.3. Product
Offerings
18.7.4. Key Developments
18.7.5. Financial
Analysis
18.7.6. SWOT
Analysis
18.7.7. Business
Strategies
18.8. Medpace
18.8.1. Company
Details
18.8.2. Company
Overview
18.8.3. Product
Offerings
18.8.4. Key
Developments
18.8.5. Financial
Analysis
18.8.6. SWOT
Analysis
18.8.7. Business
Strategies
18.9. Merck
& Co
18.9.1. Company
Details
18.9.2. Company
Overview
18.9.3. Product
Offerings
18.9.4. Key
Developments
18.9.5. Financial
Analysis
18.9.6. SWOT
Analysis
18.9.7. Business
Strategies
18.10. Novartis
AG
18.10.1. Company
Details
18.10.2. Company
Overview
18.10.3. Product
Offerings
18.10.4. Key
Developments
18.10.5. Financial
Analysis
18.10.6. SWOT
Analysis
18.10.7. Business
Strategies
18.11. Novo
Nordisk
18.11.1. Company
Details
18.11.2. Company
Overview
18.11.3. Product
Offerings
18.11.4. Key
Developments
18.11.5. Financial
Analysis
18.11.6. SWOT
Analysis
18.11.7. Business
Strategies
18.12. Pfizer
Inc
18.12.1. Company
Details
18.12.2. Company
Overview
18.12.3. Product
Offerings
18.12.4. Key
Developments
18.12.5. Financial
Analysis
18.12.6. SWOT
Analysis
18.12.7. Business
Strategies
18.13. ProSciento
+ NORDIC BIOSCIENCE
18.13.1. Company
Details
18.13.2. Company
Overview
18.13.3. Product
Offerings
18.13.4. Key
Developments
18.13.5. Financial
Analysis
18.13.6. SWOT
Analysis
18.13.7. Business
Strategies
18.14. Siemens
Healthcare GmbH
18.14.1. Company
Details
18.14.2. Company
Overview
18.14.3. Product
Offerings
18.14.4. Key
Developments
18.14.5. Financial
Analysis
18.14.6. SWOT
Analysis
18.14.7. Business
Strategies
18.15. Viking
Therapeutics
18.15.1. Company
Details
18.15.2. Company
Overview
18.15.3. Product
Offerings
18.15.4. Key
Developments
18.15.5. Financial
Analysis
18.15.6. SWOT
Analysis
18.15.7. Business
Strategies
18.16. Zydus
Cadila
18.16.1. Company
Details
18.16.2. Company
Overview
18.16.3. Product
Offerings
18.16.4. Key Developments
18.16.5. Financial
Analysis
18.16.6. SWOT
Analysis
18.16.7. Business Strategies
18.17. Other
Market Participants
19. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User
and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
